Press release
Advanced Merkel Cell Carcinoma Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight
Advanced Merkel Cell Carcinoma Clinical Trials
Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report
• DelveInsight's Advanced Merkel Cell Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
• The leading companies working in the Advanced Merkel Cell Carcinoma market include Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
• Promising Advanced Merkel Cell Carcinoma Pipeline Therapies in the various stages of development include Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
• April 2024: ImaginAb Inc. announced a study of Phase 2 clinical trials for zirconium Zr 89 crefmirlimab berdoxam. The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Request a sample and discover the recent advances in Advanced Merkel Cell Carcinoma Treatment Drugs @ Advanced Merkel Cell Carcinoma Infection Pipeline Outlook Report- https://www.delveinsight.com/sample-request/advanced-merkel-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Advanced Merkel Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Merkel Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Merkel Cell Carcinoma clinical trial landscape.
Advanced Merkel Cell Carcinoma Overview
Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease.
Find out more about Advanced Merkel Cell Carcinoma Treatment Drugs @ Drugs for Advanced Merkel Cell Carcinoma Treatment- https://www.delveinsight.com/sample-request/advanced-merkel-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Advanced Merkel cell carcinoma Emerging Drugs
• Tidutamab: Xencor, Inc.
Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor's XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.
• Cabozantinib: Exelixis
In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide.
Advanced Merkel cell carcinoma: Therapeutic Assessment
There are approx. 20+ key Advanced Merkel Cell Carcinoma companies which are developing the therapies for Advanced Merkel cell carcinoma. The companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.
DelveInsight's Advanced Merkel Cell Carcinoma pipeline report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Advanced Merkel cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
Advanced Merkel Cell Carcinoma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Advanced Merkel Cell Carcinoma Pipeline Therapies @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/advanced-merkel-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Advanced Merkel Cell Carcinoma Pipeline Report
• Coverage- Global
• Advanced Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Merkel Cell Carcinoma Companies- Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
• Advanced Merkel Cell Carcinoma Pipeline Therapies- Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
Dive deep into rich insights for new drugs for Advanced Merkel Cell Carcinoma treatment, Visit @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/advanced-merkel-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Advanced Merkel cell carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Merkel cell carcinoma - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Cabozantinib: Exelixis
9. Early Stage Products (Phase I)
10. IFx-Hu2.0: Morphogenesis
11. Inactive Products
12. Advanced Merkel cell carcinoma Key Companies
13. Advanced Merkel cell carcinoma Key Products
14. Advanced Merkel cell carcinoma- Unmet Needs
15. Advanced Merkel cell carcinoma- Market Drivers and Barriers
16. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
17. Advanced Merkel cell carcinoma Analyst Views
18. Advanced Merkel cell carcinoma Key Companies
19. Appendix
For further information on the Advanced Merkel Cell Carcinoma pipeline therapeutics, reach out to Advanced Merkel Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/advanced-merkel-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Merkel Cell Carcinoma Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight here
News-ID: 3560563 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Merkel
Rising Incidence Of Skin Cancer Fuels Growth In Merkel Cell Carcinoma Treatment …
Which drivers are expected to have the greatest impact on the over the merkel cell carcinoma treatment market's growth?
The escalating occurrence rate of skin cancer cases is likely to stimulate the merkel cell carcinoma treatment market's expansion. Skin cancer refers to a specific variety of cancer that originates in the skin cells. It transpires when skin's normal cells experience genetic mutations that make them proliferate uncontrollably, leading to the creation…
Merkel Cell Carcinoma Treatment Market 2024 Research Report
Merkel Cell Carcinoma Treatment Market
Merkel cell carcinoma treatment includes medical interventions and therapies used to manage Merkel cell carcinoma, a rare and aggressive skin cancer.
The global Merkel Cell Carcinoma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The market for Merkel cell carcinoma treatment is driven by the increasing incidence of…
Metastatic Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Metastatic Merkel Cell Carcinoma pipeline constitutes 13+ key companies continuously working towards developing 15+ Metastatic Merkel Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Metastatic Merkel Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Merkel…
Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Advanced Merkel cell carcinoma Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Merkel Cell…
Global Merkel Cell Carcinoma Treatment Market Insights, Forecast
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. The global Merkel Cell Carcinoma Treatment market is…
Merkel Cell Carcinoma - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Merkel Cell Carcinoma - Pipeline Review, H1 2017" to its huge collection of research reports.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts…
